Zevra Therapeutics reports Q2 EPS $1.21, consensus $1.38

Reports Q2 revenue $25.88M, consensus $22.49M. “This is an exciting time of growth for Zevra,” said Neil F. McFarlane, Zevra’s President and Chief Executive Officer. “Following approval late last year, we are focused on executing the U.S. launch of MIPLYFFA, and we believe the remarkable performance in the second quarter sets a strong foundation for continued momentum. As the only treatment that has been shown to halt disease progression by addressing its underlying pathology, we are invigorated by the meaningful impact MIPLYFFA is bringing to people diagnosed with Niemann-Pick disease type C. Now, with the recent submission of the Marketing Authorisation Application in the E.U., we seek to expand these differentiated benefits to greater numbers of patients with this debilitating disease.”